// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























169 Abstracts

The Difference in eGFR by Cystatin C vs. Creatinine Is Strongly Associated with Mortality Independent of Measured GFR

Potok O. Alison - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Omnipaque 350

Cystatin C Measurement Improves Renal Function Estimation with Selpercatinib Use

Gutgarts Victoria - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic kidney disease

LOXO-292

Kidney Filtration Markers in Human Saliva: Accuracy and Reproducibility of Novel Salivary Cystatin C Measurements

Kalantar-Zadeh Kamyar - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Perinatal Cystatin C as Biomarker of Nephron Endowment

Crippa Beatrice�Letizia - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cyanotic Nephropathy (CN) in Pre-Fontan Congenital Cyanotic Heart Disease (CCHD) with Solitary Kidney

Vuong KimmyThien - American Society of Nephrology (ASN) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cyanotic heart disease

N/A

Neutrophil‐Gelatinase‐Associated Lipocalin and Cystatin C Predict AKI Recovery And Dialysis In Critically Ill Cirrhotics

Rakhi Maiwall - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Glomerular Filtration Rate Based on Cystatin C Provides the Best Prediction of Cardiovascular Events and Mortality Compared to Measured GFR and Creatinine Based GFR in Kidney Transplant Recipients

L. Galapia - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Peripheral artery disease

N/A

Serum Cystatin C Predicts Kidney-Related Outcomes and Transplant-Free Survival in Patients with End-Stage Liver Disease and Low Body Mass Index

N. Shankar - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

End-stage liver disease

N/A

Elevated serum cathepsin B, procathepsin B and cystatin C in women with preeclampsia

Ho Yeon Kim - Society for Maternal-Fetal Medicine (SMFM) , 2018

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Preeclampsia

N/A

Estimated GFR by Serum Myo-inositol, Valine, Creatinine, and Cystatin-c Outperforms Current CKD-epi Equations in Renal Transplant Recipients

J. W. Meeusen - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Inositol

Urinary Exosomal Cystatin C and Lipopolysaccharide Binding Protein as Biomarkers for Monitoring Antibody-mediated Rejection After Kidney Transplantation

M. Kim - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Other

Chronic antibody mediated rejection

N/A

Performance of 2021 Creatinine and Cystatin C Based Equations without Race in Living Kidney Transplant Donors

A. Liaqat - American Transplant Congress (ATC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Serum Cystatin C is an Early Predictor of Acute Renal Injury in Infants After Cardiac Surgery With Cardiopulmonary Bypass

Maher Abadeer - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Acute renal failure

N/A

Novel Model of Oxalate Diet Induced Chronic Kidney Disease in Dahl-Salt-Sensitive Rats

Prabhatchandra Dube - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Chronic kidney disease

Angiotensin II

Cystatin C is Superior to Creatinine in Risk Prediction After Transcatheter Aortic Valve Replacement

Kensuke Kuwabara - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Comparison of the creatinine-based and the cystatin c-based estimated glomerular function (EGFR in patients with systemic sclerosis patients

M. Krusche - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Urinary Cystatin C and Neutrophil gelatinase-associated lipocalin: Novel biomarkers for detection of early kidney dysfunction in children with urolithiasis

Larisa Kovacevic - Society for Paediatric Urology (SPU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Nephrolithiasis, calcium oxalate

N/A

ASSOCIATION OF CARDIOVASCULAR DISEASE WITH BIOMARKERS IN CHRONIC KIDNEY DISEASE: BASELINE DATA FROM THE ICKD STUDY

K. Kamboj - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Mechanical Aortic Strain Promotes Expression of Proteolytic Matrix Markers in Abdominal Aortic Aneurysm

Raj Patel - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Abdominal aortic aneurysm

ILS-969

The Association of Serial Measures of Plasma Trimethylamine N-Oxide With Incident Chronic Kidney Disease and Renal Function Decline Among Older Adults The Cardiovascular Health Study

Meng Wang - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

LT 02

Copyright © 2026. QuantiNova All rights reserved